Specialized Know-How and Capacity to Support Demand for Oncolytic Viruses

News
Published: 7 May 2020 Author: Stefan Beyer, Ph.D., Chief Executive Officer and Kai Lipinski, Ph.D., Chief Scientific Officer

Few CDMOs are capable of supporting biopharma companies advancing oncolytic virus (OV) therapies toward late-stage clinical trials. Vibalogics, however, is investing in new large-scale capacity and will be positioned to provide process development through late-stage and commercial manufacturing services from state-of-the-art facilities in both the United States and Germany.

Read more here.

We’re the ideal CDMO for your Virotherapy project

Get in touch

SERVICE OFFERING

Looking for something different?

Vibalogics can assist you through a comprehensive service portfolio – ensuring success of your virotherapy, beginning with process development and technical transfer feasibility, through cGMP production and validation.

Related

What to read next

Vibalogics Completes Major Milestone in $5…

Vibalogics' expansion will provide added capacity and scalable clinical solutions for virotherapy ma…

The Medicine Maker: A New Focus for Cancer…

The Medicine Maker recently featured Joe Sinclair, Vice President, Business Development & Corporat…

GMP Manufacturing of Oncolytic Viruses: Cr…

The oncolytic virus (OV) sector needs to overcome several challenges to bring transformative cancer th…